[go: up one dir, main page]

PE20091584A1 - Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-n-metilpiridina-2-carboxamida y su sal tosilato - Google Patents

Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-n-metilpiridina-2-carboxamida y su sal tosilato

Info

Publication number
PE20091584A1
PE20091584A1 PE2009000509A PE2009000509A PE20091584A1 PE 20091584 A1 PE20091584 A1 PE 20091584A1 PE 2009000509 A PE2009000509 A PE 2009000509A PE 2009000509 A PE2009000509 A PE 2009000509A PE 20091584 A1 PE20091584 A1 PE 20091584A1
Authority
PE
Peru
Prior art keywords
amino
methylpyridine
carboxamide
chloro
compound
Prior art date
Application number
PE2009000509A
Other languages
English (en)
Inventor
Michael Logers
Reinhold Gehring
Oliver Kuhn
Mike Matthaus
Klaus-Helmut Mohrs
Matthias Muller-Gliemann
Jurgen Stiehl
Mathias Berwe
Jana Lenz
Werner Heilmann
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35457568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091584(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20091584A1 publication Critical patent/PE20091584A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Developing Agents For Electrophotography (AREA)

Abstract

SE REFIERE A UN PROCEDIMIENTO PARA PREPARAR 4-{4-[({[4-CLORO-3-(TRIFLUOROMETIL)FENIL]AMINO}CARBONIL)AMINO]FENOXI}-N-METILPIRIDINA-2-CARBOXAMIDA, QUE COMPRENDE: A) REACCIONAR CLORURO DE TIONILO CON ACIDO 2-PICOLINICO EN UN DISOLVENTE INERTE HACIA CLORURO DE TIONILO; B) REACCIONAR EL COMPUESTO RESULTANTE CON UNA SOLUCION DE METILAMINA; C) REACCIONAR COMPUESTO RESULTANTE CON 4-AMINOFENOL RESULTANDO COMPUESTO 4-(4-AMINOFENOXI)-N-METILPIRIDINA-2-CARBOXAMIDA; D) REACCIONAR COMPUESTO DEL PASO C) CON ISOCIANATO DE 4-CLORO-3-TRIFLUOROMETILFENILO RESULTANDO COMPUESTO DE FORMULA (II); Y D) REACCIONAR COMPUESTO (II) CON ACIDO p-TOLUENOSULFONICO. DICHO COMPUESTO ES INHIBIDOR DE ENZIMA Raf QUINASA SIENDO UTIL EN EL TRATAMIENTO DE TRANSTORNOS ANGIOGENICOS COMO EL CANCER
PE2009000509A 2004-09-29 2005-09-28 Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-n-metilpiridina-2-carboxamida y su sal tosilato PE20091584A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04023131 2004-09-29

Publications (1)

Publication Number Publication Date
PE20091584A1 true PE20091584A1 (es) 2009-10-28

Family

ID=35457568

Family Applications (5)

Application Number Title Priority Date Filing Date
PE2009000510A PE20091585A1 (es) 2004-09-29 2005-09-28 Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-n-metilpiridina-2-carboxamida y su sal tosilato
PE2005001144A PE20060825A1 (es) 2004-09-29 2005-09-28 Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-n-metilpiridina-2-carboxamida y su sal tosilato
PE2009000512A PE20091587A1 (es) 2004-09-29 2005-09-28 Procedimiento para preparar 4-cloro-n-metilpiridin-2-carboxamida
PE2009000509A PE20091584A1 (es) 2004-09-29 2005-09-28 Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-n-metilpiridina-2-carboxamida y su sal tosilato
PE2009000511A PE20091586A1 (es) 2004-09-29 2005-09-28 Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-n-metilpiridina-2-carboxamida y su sal tosilato

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PE2009000510A PE20091585A1 (es) 2004-09-29 2005-09-28 Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-n-metilpiridina-2-carboxamida y su sal tosilato
PE2005001144A PE20060825A1 (es) 2004-09-29 2005-09-28 Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-n-metilpiridina-2-carboxamida y su sal tosilato
PE2009000512A PE20091587A1 (es) 2004-09-29 2005-09-28 Procedimiento para preparar 4-cloro-n-metilpiridin-2-carboxamida

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2009000511A PE20091586A1 (es) 2004-09-29 2005-09-28 Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-n-metilpiridina-2-carboxamida y su sal tosilato

Country Status (34)

Country Link
US (1) US8124782B2 (es)
EP (1) EP1797037B1 (es)
JP (2) JP2008514657A (es)
KR (1) KR101263032B1 (es)
CN (1) CN101052619B (es)
AR (1) AR053973A1 (es)
AU (1) AU2005289099B2 (es)
BR (1) BRPI0515944B1 (es)
CA (1) CA2581835C (es)
CU (1) CU23754B7 (es)
CY (1) CY1116126T1 (es)
DK (1) DK1797037T3 (es)
DO (1) DOP2005000183A (es)
EC (1) ECSP077357A (es)
ES (1) ES2532377T3 (es)
GT (1) GT200500269A (es)
HN (1) HN2005000768A (es)
HR (1) HRP20150295T1 (es)
IL (1) IL182046A0 (es)
MA (1) MA28883B1 (es)
MY (1) MY149873A (es)
NO (1) NO339647B1 (es)
NZ (1) NZ554119A (es)
PE (5) PE20091585A1 (es)
PL (1) PL1797037T3 (es)
PT (1) PT1797037E (es)
SG (1) SG155997A1 (es)
SI (1) SI1797037T1 (es)
SV (1) SV2006002243A (es)
TW (1) TWI382973B (es)
UA (1) UA90691C2 (es)
UY (1) UY29143A1 (es)
WO (1) WO2006034796A1 (es)
ZA (1) ZA200702511B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2384160T3 (es) 1999-01-13 2012-07-02 Bayer Healthcare Llc Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1478358B1 (en) 2002-02-11 2013-07-03 Bayer HealthCare LLC Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
DK1626714T3 (da) 2003-05-20 2007-10-15 Bayer Pharmaceuticals Corp Dirarylurinstoffer mod sygdomme medieret af PDGFR
EA010485B1 (ru) 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
BRPI0515946A (pt) * 2004-09-29 2008-08-12 Bayer Healthcare Ag sal de tosilato, sua preparação e uso, bem como composição farmacêutica compreendendo o mesmo
HRP20150295T1 (hr) 2004-09-29 2015-05-22 Bayer Healthcare Llc Postupak za pripravu 4-{4-[({[4-kloro-3-(trifluorometil)fenil]amino}karbonil)amino]fenioksi}n-metilpiridin-2-karboksamida
WO2006094626A1 (en) 2005-03-07 2006-09-14 Bayer Healthcare Ag Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
US20100113533A1 (en) * 2006-11-14 2010-05-06 Bayer Schering Pharma Aktiengesellschaft Polymorph II of 4-[4-(Amino)-3- Fluorophenoxy]-N-Methylpyridine-2-Carboxamide
CA2698795C (en) 2007-09-10 2016-04-19 Cipla Limited Process for the preparation of a raf kinase inhibitor and intermediates for use in the process
WO2009054004A2 (en) * 2007-10-22 2009-04-30 Natco Pharma Limited Process for the preparation of sorafenib
EP2231612A1 (en) * 2008-01-17 2010-09-29 Sicor, Inc. Polymorph form iii of sorafenib tosylate, sorafenib tosylate methanol solvate and sorafenib tosylate ethanol solvate, and processes for preparation thereof
WO2009111061A1 (en) * 2008-03-06 2009-09-11 Sicor Inc. Process for the preparation of sorafenib and salts thereof
CN103254126A (zh) * 2008-09-19 2013-08-21 苏州泽璟生物制药有限公司 氘代的ω-二苯基脲及衍生物以及包含该化合物的药物组合物
CA2775229C (en) 2009-09-24 2014-07-29 Ranbaxy Laboratories Limited Process for the preparation of sorafenib tosylate
CA2775296A1 (en) 2009-09-24 2011-03-31 Ranbaxy Laboratories Limited Polymorphs of sorafenib acid addition salts
EP2499116A1 (en) 2009-11-12 2012-09-19 Ranbaxy Laboratories Limited Sorafenib ethylsulfonate salt, process for preparation and use
WO2011076711A2 (en) 2009-12-23 2011-06-30 Ratiopharm Gmbh Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methylpyridine-2-carboxamide
PL2528899T3 (pl) 2010-01-29 2015-02-27 Ranbaxy Laboratories Ltd Solwat sorafenibu z dimetylosulfotlenkiem
CN102190616B (zh) * 2010-03-18 2015-07-29 苏州泽璟生物制药有限公司 一种氘代的ω-二苯基脲的合成及生产的方法和工艺
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
CN102617458A (zh) * 2010-05-18 2012-08-01 张南 抗癌用化合物的制备方法
EP2595628A1 (en) 2010-07-19 2013-05-29 Bayer HealthCare LLC Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
CA2813069A1 (en) 2010-10-01 2012-04-05 Bayer Intellectual Property Gmbh Substituted n-(2-arylamino)aryl sulfonamide-containing combinations
WO2012071425A1 (en) 2010-11-22 2012-05-31 Teva Pharmaceutical Industries Ltd. Solid state forms of sorafenib besylate, and processes for preparations thereof
EP2559431A1 (en) 2011-08-17 2013-02-20 Ratiopharm GmbH Pharmaceutical composition comprising 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
CN103664771B (zh) * 2012-09-19 2016-03-30 齐鲁制药有限公司 索拉非尼的晶型a及其制备方法
WO2014118807A1 (en) * 2013-02-04 2014-08-07 Intas Pharmaceuticals Limited A novel process for the preparation of sorafenib tosylate form iii
CN104710354A (zh) * 2013-12-13 2015-06-17 江苏豪森药业股份有限公司 高纯度索拉非尼的制备方法
CN104761492A (zh) * 2014-01-03 2015-07-08 正大天晴药业集团股份有限公司 对甲苯磺酸索拉非尼的晶型及其制备方法
CN104177292A (zh) * 2014-08-08 2014-12-03 亿腾药业（泰州）有限公司 一种工业化生产甲苯磺酸索拉非尼多晶型ⅰ的方法
CN110204483B (zh) * 2014-12-01 2021-06-29 石药集团中奇制药技术（石家庄）有限公司 一种甲苯磺酸索拉非尼新晶型及其制备方法
EP3109236B1 (en) 2015-06-23 2017-08-09 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Scalable process for the preparation of sorafenib tosylate ethanol solvate and sorafenib tosylate form iii
CN105181844A (zh) * 2015-09-11 2015-12-23 江苏嘉逸医药有限公司 一种高效液相色谱法测定甲苯磺酸索拉非尼含量和有关物质的方法
CN105585523A (zh) * 2015-12-29 2016-05-18 上海北卡医药技术有限公司 一种对甲苯磺酸索拉非尼的新晶型及其制备方法和用途
CN107840823B (zh) * 2016-09-20 2021-08-17 意大利合成制造有限公司 用于制备甲苯磺酸索拉非尼乙醇溶剂化物和iii型甲苯磺酸索拉非尼的可变规模的方法
CN107915676A (zh) * 2017-10-26 2018-04-17 魏海霞 索拉非尼的制备方法
CN109796400B (zh) * 2017-11-16 2022-07-29 四川科伦药物研究院有限公司 一种甲苯磺酸索拉菲尼晶型及其制备方法
CN113773249A (zh) * 2020-06-10 2021-12-10 杭州中美华东制药有限公司 索拉非尼游离碱晶型Form X及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU86960A1 (fr) * 1987-07-31 1989-03-08 Oreal Procede de preparation de piperidino-6 diamino-2,4 pyrimidine oxyde-3 et composes nouveaux
JPH02934A (ja) * 1988-05-27 1990-01-05 Konica Corp 非線形光学材料
JP2971291B2 (ja) * 1993-06-02 1999-11-02 田辺製薬株式会社 光学活性２−アミノ酪酸の製法
JP3866323B2 (ja) * 1996-03-27 2007-01-10 ポーラ化成工業株式会社 新規ｎ−ベンジルベンズアミド誘導体
JPH09316069A (ja) * 1996-03-28 1997-12-09 Ajinomoto Co Inc 新規キサントン誘導体
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
DE122006000059I1 (de) * 1999-01-13 2007-02-15 Bayer Pharmaceuticals Corp -G(V)-Carboxyaryl substituierte Diphenyl Harnstoffe als Raf Kinase Inhibitoren
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
GB2367816A (en) * 2000-10-09 2002-04-17 Bayer Ag Urea- and thiourea-containing derivatives of beta-amino acids
PT2305255E (pt) 2001-12-03 2012-09-04 Bayer Healthcare Llc Compostos de arilureia em combinação com outros agentes citostáticos ou citotóxicos para tratamento de cancros humanos
US20030207872A1 (en) * 2002-01-11 2003-11-06 Bayer Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
DE10203086A1 (de) * 2002-01-28 2003-07-31 Bayer Ag 5-Ring Heterozyklen
EP1478358B1 (en) * 2002-02-11 2013-07-03 Bayer HealthCare LLC Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
KR20050087776A (ko) * 2002-08-13 2005-08-31 산도즈 아게 세프디니르 중간체
JP3763414B2 (ja) * 2002-10-21 2006-04-05 麒麟麦酒株式会社 Ｎ−｛２−クロロ−４−［（６，７−ジメトキシ−４−キノリル）オキシ］フェニル｝−ｎ’−（５−メチル−３−イソキサゾリル）ウレアの塩の結晶形
DK1626714T3 (da) * 2003-05-20 2007-10-15 Bayer Pharmaceuticals Corp Dirarylurinstoffer mod sygdomme medieret af PDGFR
HRP20150295T1 (hr) 2004-09-29 2015-05-22 Bayer Healthcare Llc Postupak za pripravu 4-{4-[({[4-kloro-3-(trifluorometil)fenil]amino}karbonil)amino]fenioksi}n-metilpiridin-2-karboksamida

Also Published As

Publication number Publication date
AU2005289099A1 (en) 2006-04-06
EP1797037B1 (en) 2014-12-17
CA2581835C (en) 2012-12-18
HN2005000768A (es) 2010-09-17
UA90691C2 (en) 2010-05-25
SV2006002243A (es) 2006-10-13
SG155997A1 (en) 2009-10-29
ZA200702511B (en) 2008-07-30
CU20070069A7 (es) 2010-11-27
CY1116126T1 (el) 2017-02-08
AR053973A1 (es) 2007-05-30
PT1797037E (pt) 2015-03-17
MY149873A (en) 2013-10-31
GT200500269A (es) 2006-05-11
PE20060825A1 (es) 2006-10-20
PE20091587A1 (es) 2009-11-05
CA2581835A1 (en) 2006-04-06
PL1797037T3 (pl) 2015-07-31
DOP2005000183A (es) 2006-03-31
HRP20150295T1 (hr) 2015-05-22
PE20091585A1 (es) 2009-10-31
KR20070058676A (ko) 2007-06-08
US20080262236A1 (en) 2008-10-23
EP1797037A1 (en) 2007-06-20
WO2006034796A1 (en) 2006-04-06
AU2005289099B2 (en) 2012-07-19
KR101263032B1 (ko) 2013-05-09
DK1797037T3 (en) 2015-03-30
BRPI0515944B1 (pt) 2021-11-09
NZ554119A (en) 2010-07-30
JP2008514657A (ja) 2008-05-08
BRPI0515944A (pt) 2008-08-12
HK1113484A1 (en) 2008-10-03
CN101052619A (zh) 2007-10-10
SI1797037T1 (sl) 2015-06-30
CN101052619B (zh) 2012-02-22
IL182046A0 (en) 2007-07-24
ES2532377T3 (es) 2015-03-26
JP5583190B2 (ja) 2014-09-03
US8124782B2 (en) 2012-02-28
NO339647B1 (no) 2017-01-16
UY29143A1 (es) 2006-04-28
CU23754B7 (es) 2012-01-31
MA28883B1 (fr) 2007-09-03
ECSP077357A (es) 2007-04-26
TW200626551A (en) 2006-08-01
TWI382973B (zh) 2013-01-21
JP2013067625A (ja) 2013-04-18
NO20072173L (no) 2007-06-14
PE20091586A1 (es) 2009-10-31

Similar Documents

Publication Publication Date Title
PE20091584A1 (es) Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-n-metilpiridina-2-carboxamida y su sal tosilato
Jabarullah et al. Methods for the direct synthesis of thioesters from aldehydes: a focus review
Zuo et al. Highly Chemoselective Transamidation of Unactivated Tertiary Amides by Electrophilic N− C (O) Activation by Amide‐to‐Acyl Iodide Re‐routing
Jamir et al. Environmentally benign one-pot synthesis of cyanamides from dithiocarbamates using I2 and H2O2
EA200400980A1 (ru) Ингибиторы асс
Hosseinian et al. A walk around the decarboxylative CS cross-coupling reactions
NO20061107L (no) CRF-antagonister og heterobrcykliske forbindelser
EA201000562A1 (ru) Производные n-(пиразол-3-ил)бензамида в качестве активаторов глюкокиназы
PE20090758A1 (es) Un proceso para la preparacion de compuestos de aminodiol protegidos con oxazolina, utiles como intermediarios para florfenicol
NO20051546L (no) Indoler med anti-diabetisk aktivitet
PE20061025A1 (es) Anilidas de acido pirazolcarboxilico
UA91520C2 (en) Thermodynamically stable form of tosylate
NZ607794A (en) N-acylsulfonamide apoptosis promoters
DK2021336T3 (da) 11-beta-hydroxysteroid-dehydrogenase-1-inhibitorer
NO20075000L (no) Kondenserte aromatiske forbindelser med anti-diabetisk aktivitet
PE20061422A1 (es) Tigeciclina y metodos para preparar 9-nitrominociclina
Wan Zullkiplee et al. Bis-thiourea bearing aryl and amino acids side chains and their antibacterial activities
Cellnik et al. Sulfonyl chlorides as thiol surrogates for carbon–sulfur bond formation: One-pot synthesis of thioethers and thioesters
BR112015029004A2 (pt) processo para a preparação de dicarbamatos de produtos de redução de hmf, composto químico precursor, composto químico derivado a partir de pelo menos um dos compostos químicos precursores, e, método de preparação de um composto químico derivado a partir de pelo menos um dos compostos químicos precursores
AR093454A1 (es) Piridiloxialquilcarboxamidas y su uso como endoparasiticidas y nematicidas
RU2014119705A (ru) Пиридин-сульфоксимины в качестве ингибиторов киназы
NZ751217A (en) Benzo-fused heterocyclic derivatives useful as agonists of gpr120
Wang et al. Condition-Controlled O-Acylation and N–O Bond Reduction of Hydroximic Acids with Thioacetic Acid
UY28200A1 (es) Acidos carboxílicos de heteroarilo condensado como agonistas del ppar
AR037679A1 (es) Un procedimiento para preparar una mezcla de rotameros de 4-[4-[(1r)-[4-(trifluormetil) fenil]-2-metoxietil] - (3s) - metil - 1- piperazinil] - 4- metil-1-[4,6-dimetil-5-pirimidinil) carbonilo], una mezcla de rotameros preparado por dicho procedimiento, y sales farmaceuticas de dicho compuesto basic

Legal Events

Date Code Title Description
FG Grant, registration